MGMT and glioma: The use of perfusion imaging-derived radiomic features has shown promising feasibility in predicting MGMT promoter methylation [34] and IDH mutation status [216,217,218,219] and for improving the differential diagnosis of gliomas [220], the diagnostic performance of tumor grading [215,221] as well as pseudoprogression [222,223,224], but also prognostication [225].